Literature DB >> 17638298

Progressive oxidative damage in the central nervous system of a murine model for juvenile Batten disease.

Jared W Benedict1, Crosby A Sommers, David A Pearce.   

Abstract

Oxidative damage is a known contributor to the pathogenesis of neurodegenerative diseases. Juvenile Batten disease is a progressive neurodegenerative disorder of childhood that results from mutation in Cln3. We have performed an initial characterization of the oxidative burden throughout the CNS in a Cln3(-/-) mouse model for juvenile Batten disease. A survey of multiple regions of the Cln3(-/-) mouse brain revealed a specific reduction of total glutathione, a tripeptide antioxidant molecule, in the cerebellum. Further analysis revealed an increase in protein oxidation not only in the cerebellum but also in the thalamus and primary motor cortex. Additionally, the thalamus was found to have an increase in the amount of a potent antioxidant enzyme, manganese superoxide dismutase (MnSOD), which may be in response to an increase in deleterious superoxide radicals. Colocalization studies indicate that microglia are localized directly adjacent to neurons expressing MnSOD, indicating that microglial activation may be related to the observed oxidative damage. This study helps to provide an initial measure of regions within the CNS of Cln3(-/-) mice that are specifically affected by the loss of CLN3 function and may serve to identify at the neuroanatomical level, the sequence of events that plays a role in the pathogenesis and clinical course of juvenile Batten disease. 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638298     DOI: 10.1002/jnr.21416

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  7 in total

1.  Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease.

Authors:  Attila D Kovács; Angelika Saje; Andrew Wong; Serena Ramji; Jonathan D Cooper; David A Pearce
Journal:  Neuropharmacology       Date:  2012-06-06       Impact factor: 5.250

2.  Fibrates inhibit the apoptosis of Batten disease lymphoblast cells via autophagy recovery and regulation of mitochondrial membrane potential.

Authors:  Minho Hong; Ki Duk Song; Hak-Kyo Lee; SunShin Yi; Yong Seok Lee; Tae-Hwe Heo; Hyun Sik Jun; Sung-Jo Kim
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-12-10       Impact factor: 2.416

3.  Antigen presenting cell abnormalities in the Cln3(-/-) mouse model of juvenile neuronal ceroid lipofuscinosis.

Authors:  Samantha L Hersrud; Attila D Kovács; David A Pearce
Journal:  Biochim Biophys Acta       Date:  2016-04-19

4.  Alterations in striatal dopamine catabolism precede loss of substantia nigra neurons in a mouse model of juvenile neuronal ceroid lipofuscinosis.

Authors:  Jill M Weimer; Jared W Benedict; Yasser M Elshatory; Douglas W Short; Denia Ramirez-Montealegre; Deborah A Ryan; Noreen A Alexander; Howard J Federoff; Jonathan D Cooper; David A Pearce
Journal:  Brain Res       Date:  2007-05-21       Impact factor: 3.252

5.  The Batten disease gene CLN3 is required for the response to oxidative stress.

Authors:  Richard I Tuxworth; Haiyang Chen; Valerie Vivancos; Nancy Carvajal; Xun Huang; Guy Tear
Journal:  Hum Mol Genet       Date:  2011-03-03       Impact factor: 6.150

6.  Glial cells are functionally impaired in juvenile neuronal ceroid lipofuscinosis and detrimental to neurons.

Authors:  Lotta Parviainen; Sybille Dihanich; Greg W Anderson; Andrew M Wong; Helen R Brooks; Rosella Abeti; Payam Rezaie; Giovanna Lalli; Simon Pope; Simon J Heales; Hannah M Mitchison; Brenda P Williams; Jonathan D Cooper
Journal:  Acta Neuropathol Commun       Date:  2017-10-17       Impact factor: 7.801

7.  Immunomodulation with minocycline rescues retinal degeneration in juvenile neuronal ceroid lipofuscinosis mice highly susceptible to light damage.

Authors:  Katharina Dannhausen; Christoph Möhle; Thomas Langmann
Journal:  Dis Model Mech       Date:  2018-09-05       Impact factor: 5.758

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.